Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design
Future Oncology
July 1, 2022
Myelofibrosis (MF)Clinical Data
Publications & Presentations
Advancing scientific understanding from research to real-world evidence.
Every study contributes to a deeper understanding of blood cancer and the potential for new treatment approaches. Through clinical trials, real-world evidence, investigator-sponsored research, and scientific collaboration, Geron is committed to generating evidence that may help advance science, inform clinical practice, and improve outcomes for people living with blood cancer.
Explore our scientific publications and presentations:
This page may contain non-exhaustive scientific information about post-hoc, exploratory, subgroup analyses, or uses that have not yet been approved by regulatory authorities. The information is provided for educational and scientific exchange purposes only, and does not suggest products should be used in a manner not consistent with their respective label approved by the regulatory authorities, which may differ by geography. Any publication reflects the state of knowledge at the time it was published. The information is not medical advice and cannot replace the independent medical judgement of a healthcare professional.